U.S. DOE awards Verenium additional $4.9M for development of cellulosic ethanol biorefinery plants

Verenium Corporation (Nasdaq: VRNM), a pioneer in the development of next-generation cellulosic ethanol and high-performance specialty enzymes, today announced that it has been awarded an additional $4.9 million from the U.S. Department of Energy (DOE) to fund ongoing activities at its demonstration-scale facility in Jennings, Louisiana.  This cooperative agreement is an extension of the grant previously awarded to the Company in July of 2008 under a DOE program supporting the development of demonstration-scale cellulosic ethanol biorefinery plants.  

"We are very pleased to receive this additional funding from the DOE, particularly given the critical work currently being performed at Jennings to optimize our cellulosic process," said Carlos A. Riva, President and Chief Executive Officer at Verenium.  "I believe this award demonstrates further the DOE's support for our technology and commitment to developing a cellulosic ethanol supply industry."

The Company plans to use the additional funds to support on-going cellulosic technology and process optimization at its Jennings, LA demonstration facility.

SOURCE Verenium Corporation

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Transcranial ultrasound stimulation: A new frontier in noninvasive brain therapy